SecBot SecBot
PRESS-RELEASE ·Filed May 31, 2026

RVMD

Revolution Medicines, Inc.
BULLISH
Impact 8/10
Horizonimmediate Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a best-case Phase 3 readout for a pivotal asset. Expect significant upside at open. Monitor the NDA submission timeline and potential accelerated approval. The expanded access protocol signals FDA alignment. Long-term, watch for data in first-line PDAC and NSCLC trials which expand the addressable market.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$163.68
T+0 close · May 31, 2026 · via day close
Latest settled
+29.14%
T+60 · $211.38
Vs SPY
+27.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $163.68entry
  2. T+1 · 6mo ago −7.56%α −7.70% · $151.31
  3. T+5 · 5mo ago −8.83%α −6.08% · $149.23
  4. T+20 · 5mo ago +14.42%α +15.72% · $187.28
  5. T+60 · 3mo ago +29.14%α +27.91% · $211.38

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines reported overwhelmingly positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer, showing a 60% reduction in risk of death and median OS of 13.2 months vs 6.6 months for chemotherapy. The company plans to file an NDA using a priority voucher, and the FDA has authorized an expanded access protocol. These results position daraxonrasib as a potential new standard of care in a high-unmet-need indication.

Key Facts

  • Phase 3 RASolute 302 trial met all primary and key secondary endpoints in previously treated metastatic PDAC.
  • Daraxonrasib reduced risk of death by 60% (HR 0.40) in both RAS G12 and ITT populations.
  • Median OS: 13.2 months daraxonrasib vs 6.6 months chemotherapy in RAS G12 population.
  • Median PFS: 7.3 months daraxonrasib vs 3.5 months chemotherapy in RAS G12 population.
  • Objective response rate: 33.2% daraxonrasib vs 11.8% chemotherapy in RAS G12 population.
  • Grade 3+ TRAEs: 43.6% daraxonrasib vs 57.5% chemotherapy; discontinuation rate 1.2% vs 11.2%.
  • Company intends to submit NDA using FDA Commissioner's National Priority Voucher.
  • FDA authorized expanded access treatment protocol (EAP) for daraxonrasib.
  • Daraxonrasib has Breakthrough Therapy and Orphan Drug designations for this indication.

Financial Impact

Transformative for a $33.5B market cap company with no approved products. Daraxonrasib could address a ~$5B+ annual market in second-line metastatic PDAC alone, with additional Phase 3 trials in first-line PDAC and NSCLC. The data support rapid regulatory filing and potential blockbuster revenue.

revenuepipeline valueregulatory probability

Risk Factors

  • Regulatory approval is not guaranteed; FDA may request additional data or have concerns about the single Grade 5 pneumonitis event.
  • Competition from other RAS inhibitors in development (e.g., from Amgen, Mirati/BMS) could emerge.
  • Commercial execution risk: launching a novel oral therapy requires new infrastructure for a company with no prior commercial products.
  • Payer reimbursement dynamics for a high-cost targeted therapy in a palliative setting.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303919

US Market Status

Market Closed · Opens Wed (9h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 31, 2026